N-[2-[6-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]-3-pyrazol-1-ylbenzamide | 1093623-49-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[2-[6-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]-[1,3]thiazolo[5,4-b]pyridin-2-yl]phenyl]-3-pyrazol-1-ylbenzamide
• CAS: 1093623-49-4
• 化学式: C₃₀H₃₁N₇O₂S
• 分子量: 553.688
• InChiKey: MSFNHWSTDFHGMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  117
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Sirtuin modulating compounds
  申请人：Bemis Jean

  公开号：US20090105246A1

  公开（公告）日：2009-04-23

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新型的调节Sirtuin的化合物及其使用方法。这些Sirtuin调节化合物可用于增加细胞寿命，并治疗/预防各种疾病和疾病，包括与衰老或压力相关的疾病或疾病、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血凝障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾病。还提供了包含Sirtuin调节化合物与另一种治疗剂组合的组合物。
• SIRTUIN MODULATING COMPOUNDS
  申请人：Bemis Jean

  公开号：US20110152254A1

  公开（公告）日：2011-06-23

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的调节Sirtuin的化合物及其使用方法。这些Sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或应激有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块疾病，炎症，癌症和/或红斑病，以及需要增加线粒体活性的疾病或疾病。还提供了包含Sirtuin调节化合物与另一种治疗剂组合的组合物。
• US7893086B2
  申请人：——

  公开号：US7893086B2

  公开（公告）日：2011-02-22
• US8268862B2
  申请人：——

  公开号：US8268862B2

  公开（公告）日：2012-09-18
• [EN] SIRTUIN MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULANT LES SIRTUINES
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2008156869A2

  公开（公告）日：2008-12-24

  [EN] Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.
  [FR] L'invention concerne de nouveaux composés modulant les sirtuines et leurs méthodes d'utilisation. Ces composés modulant les sirtuines peuvent être utilisés pour prolonger la durée de vie d'une cellule et pour traiter et/ou prévenir un grand nombre de maladies et de troubles, y compris, par exemple, des maladies et des troubles liés au vieillissement et au stress, le diabète, l'obésité, des maladies neurodégénératives, une maladie cardiovasculaire, des troubles de la coagulation sanguine, l'inflammation, le cancer, et/ou les bouffées vasomotrices, ainsi que des maladies ou des troubles pouvant bénéficier d'une activité mitochondriale plus intense. L'invention concerne également des compositions comprenant un composé modulant les sirtuines, combiné à un autre agent thérapeutique.